Shiqi Cao Selected Research

methyl 4-(adenin-9-yl)-2-hydroxybutanoate

2/2021

DZ2002 alleviates psoriasis-like skin lesions via differentially regulating methylation of GATA3 and LCN2 promoters.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Shiqi Cao Research Topics

Disease

2	Spinal Stenosis (Stenosis, Spinal) 09/2021 - 08/2019
1	Kinesiophobia 01/2022
1	Disease Progression 10/2021
1	Antiphospholipid Syndrome (Antiphospholipid Antibody Syndrome) 10/2021
1	Osteoporosis 05/2021
1	Inflammation (Inflammations) 02/2021
1	Psoriasis (Pustulosis Palmaris et Plantaris) 02/2021
1	Osteoarthritis 01/2021
1	Esophageal Neoplasms (Esophageal Cancer) 01/2018

Drug/Important Bio-Agent (IBA)

1	4-amino-4'-hydroxylaminodiphenylsulfone (HADS)IBA 01/2022
1	beta-aminoarteether maleateIBA 10/2021
1	Antiphospholipid AntibodiesIBA 10/2021
1	artemisinin (artemisinine)IBA 10/2021
1	Proteins (Proteins, Gene)FDA Link 05/2021
1	isobavachalconeIBA 05/2021
1	methyl 4-(adenin-9-yl)-2-hydroxybutanoateIBA 02/2021
1	HomocysteineIBA 02/2021
1	HydrolasesIBA 02/2021
1	SodiumIBA 01/2021
1	pyrazoleIBA 01/2021
1	Therapeutic UsesIBA 01/2021
1	Biological ProductsIBA 01/2021
1	Betulinic AcidIBA 01/2021

Therapy/Procedure

2	Decompression 09/2021 - 08/2019
1	Laminectomy 09/2021
1	Esophagectomy 01/2018